inflammatory bowel diseases

Overview

Inflammatory bowel diseases (IBD) are a group of chronic, relapsing inflammatory disorders of the gastrointestinal tract, most prominently Crohn’s disease and ulcerative colitis. They are characterized by persistent intestinal inflammation, mucosal barrier dysfunction, microbiota dysbiosis, and immune dysregulation, with contributions from epithelial, immune, and stromal compartments. Recent literature also emphasizes the role of oxidative stress, pyroptosis, and altered cytokine signaling in sustaining tissue injury and chronic disease activity.

Clinically, IBD is associated with diarrhea, bleeding, impaired quality of life, and an increased risk of complications such as colorectal cancer. Disease burden is substantial in both adults and children, and pediatric IBD is often described as presenting with more aggressive phenotypes while therapeutic options remain comparatively limited. Because of its heterogeneity and complex biology, IBD is now a major focus of precision medicine, biomarker discovery, multimodal phenotyping, and advanced drug-delivery research.

Focus of Latest Publications

Recent publications portray IBD as a highly active area of translational research spanning clinical therapeutics, biomarker development, systems biology, and engineered delivery platforms. Several studies focused on the therapeutic landscape, including benefit-risk considerations for advanced therapies in pediatric IBD, real-world use of advanced combined therapies, and the ongoing challenge of secondary loss of response to infliximab. One mechanistic study linked pathogenic Th17 cells to mucosal inflammation and secondary loss of response to infliximab, reinforcing the importance of IL17A-associated immune pathways in treatment failure. Another line of work examined regulatory T cells, highlighting their plasticity, dysfunction, and potential for therapeutic reprogramming in immune-mediated intestinal inflammation.

A major theme across the recent literature is the move toward precision medicine and multimodal disease characterization. The IBDome atlas integrated molecular, histopathological, and clinical data to refine diagnostics and support personalized therapeutic strategies. Related studies emphasized that assessment of IBD increasingly depends on combining endoscopy, histology, cross-sectional imaging, and omics data. artificial intelligence and deep learning were presented as tools to integrate these heterogeneous data streams, with the goal of improving disease activity assessment, outcome prediction, and biomarker discovery. Multimodal deep learning, convolutional neural networks, computational pipelines, and artificial learning models were all framed as part of a broader effort to translate complex molecular and clinical signatures into usable decision support.

Several studies investigated the microbiota-metabolite-immune axis in IBD. Habitual ultra-processed food intake was associated with gut dysbiosis and pro-inflammatory metabolite profiles in Korean patients with IBD, supporting the idea that diet can influence microbial ecology relevant to disease activity. Other work described the gut microbiota as a key factor in IBD pathophysiology and a source of diagnostic innovation. Reviews and experimental studies also pointed to microbiota-targeted or food-derived interventions, including beta-glucan, curcumin, berberine, tannic acid, chestnut wood extract, and medicinal and edible plants, as candidate modulators of inflammation, oxidative stress, and microbial balance. In parallel, multi-omics studies identified fibroblast subtypes with distinct roles in IBD, underscoring the contribution of stromal biology to chronic intestinal inflammation.

Engineered therapeutic delivery systems were another prominent research direction. Investigators reported targeted and quantitatively modeled biologic delivery via dual-functional probiotic yeast in an IBD mouse model, ROS-responsive nanoparticles designed to suppress pyroptosis and cell-free DNA, food-derived biohybrid probiotic extracellular vesicles, curcumin-loaded extracellular vesicles from lactic acid bacteria, and red-light-activated living bacterial electron generators for on-demand drug release in colonic inflammation. These studies collectively reflect a push toward spatiotemporally precise delivery in a disease where conventional systemic therapy can be limited by incomplete efficacy, adverse effects, and variable gut redox conditions. Related preclinical work also explored cationic nanoparticles, chitosan-based systems, azo-bond covalent organic frameworks, AM1 peptide-based platforms, and 2 kDa PEG modification as components of engineered delivery strategies.

The recent literature also highlights the expanding use of biomarkers and diagnostic assays. Fecal calprotectin was described as a crucial non-invasive biomarker for diagnosing and monitoring IBD, and a novel latex particle-enhanced turbidimetric immunoassay was developed and validated for this purpose. Blood-based biomarkers were evaluated in pregnant women with IBD, reflecting the need for monitoring tools in special populations. Additional studies discussed diagnostic biomarkers, CA19-9, and multimodal molecular measures as part of broader efforts to improve disease stratification. One publication also noted that IBD can be complicated by kidney disease, including rare membranous nephropathy, illustrating the systemic and extraintestinal relevance of the disorder.

Finally, several studies used experimental models to probe mechanisms and test interventions. DSS-induced colitis mice, DSS-induced colitis mouse models, DSS-induced UC mouse models, and 2,4,6-trinitrobenzene sulfonic acid colitis models were used to evaluate anti-inflammatory effects, immune modulation, and barrier protection. Zebrafish models, including adult female zebrafish, were also used in mechanistic and screening studies. Across these systems, pathways involving nuclear factor kappa B, nuclear factor kappa B, oxidative stress, superoxide dismutase, CASP1, ferroptosis, and anti-inflammatory cytokines were repeatedly implicated. Together, these studies depict IBD as a disease at the intersection of immunology, microbiology, epithelial biology, and computational medicine.

Key Publications

• Jun Benefit-risk balance of advanced therapies in pediatric inflammatory bowel disease: evidence and gaps versus adults. (Inflammatory bowel diseases, 2026, PMID 42334183): "Although the incidence of pediatric Inflammatory Bowel Diseases (IBD) continues to rise globally, often presenting with more aggressive phenotypes than in adults, the therapeutic arsenal available for children lags significantly behind."
• Jun Habitual Ultra-processed Food Intake Is Associated with Gut Dysbiosis and Pro-inflammatory Metabolite Profiles in Korean Patients with IBD. (Digestive diseases and sciences, 2026, PMID 42319657): "Ultra-processed food (UPF) is increasingly consumed worldwide and may influence gut microbial ecology relevant to inflammatory bowel disease (IBD)."
• Jun Membranous nephropathy secondary to very early-onset inflammatory bowel disease in a 3-year-old boy: case report. (CEN case reports, 2026, PMID 42315775): "Inflammatory bowel disease (IBD) can be complicated by kidney disease, but IBD complicated by MN is rarely reported."
• Jun Entering a new age of innovation in IBD clinical trial design. (Med (New York, N.Y.), 2026, PMID 42285045): "With a growing number of molecules to investigate as potential treatments for inflammatory bowel disease, an important advance has been through the use of more innovative and novel trial designs."
• Jun Relationships between periodontitis and inflammatory bowel disease: Screening and functional analysis of endoplasmic reticulum stress-related biomarkers. (Biochemical and biophysical research communications, 2026, PMID 41967449): "PD and IBD significantly affect global health, and current treatments have limitations."
• Jun IBDome: An integrated molecular, histopathological, and clinical atlas of inflammatory bowel diseases. (Gastroenterology, 2026, PMID 42269946): "Multi-omic and multimodal datasets with detailed clinical annotations offer significant potential to advance our understanding of inflammatory bowel diseases (IBD), refine diagnostics, and enable personalized therapeutic strategies."
• Jun Targeted and quantitatively modeled biologic delivery via dual-functional probiotic yeast in inflammatory bowel disease. (Journal of controlled release : official journal of the Controlled Release Society, 2026, PMID 41942055): "...pharmacokinetic validation in an inflammatory bowel disease (IBD) mouse model."
• Jun Dual-action ROS-responsive nanoparticles for synergistic suppression of pyroptosis and cfDNA in inflammatory bowel diseases. (Journal of controlled release : official journal of the Controlled Release Society, 2026, PMID 41985747): "Pyroptosis-induced production of inflammatory cytokines and elevated levels of cell-free DNA (cfDNA) are major pathogenic drivers of intestinal inflammatory diseases."
• Jun Artificial intelligence in inflammatory bowel disease: From current evidence, clinical translation, and the road to precision medicine. (Chinese medical journal, 2026, PMID 42268244): "Inflammatory bowel diseases (IBD) are complex, heterogeneous conditions whose assessment relies on integrating several modalities, including endoscopy, histology, cross-sectional imaging, and omics data, all of which are critical for evaluating disease activity and predicting long-term outcomes."
• Jun Multi-omics reveals fibroblast subtypes with distinct roles in inflammatory bowel disease. (Biology direct, 2026, PMID 42265813): "Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract involving complex interactions among epithelial, immune, and stromal components."